Wolverine Asset Management’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Wolverine Asset Management’s Portfolio BIOTU Stock Details BIOTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,028	Closed	-$10K	–	2661
2022 Q1	$10K	Buy	+1,028	New	+$10.3K	﹤0.01%	1903
2021 Q2	–	Sell	-194,844	Closed	-$1.93M	–	2512
2021 Q1	$1.93M	Buy	+194,844	New	+$2M	0.02%	438

Other funds holding BIOTU

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wolverine Asset Management's BIOTU Position: Q2 2022 in Review

Wolverine Asset Management sold out of Biotech Acquisition Company Unit (BIOTU) in Q2 2022, closing a stake of 1,028 shares — an estimated $10K sold.

Wolverine Asset Management first reported a position in BIOTU in Q1 2021 and held it in 2 quarters. The position peaked at $1.93M in Q1 2021. 5 funds tracked by Wall St. Rank hold BIOTU as of Q2 2022.

Wolverine Asset Management reported no remaining Biotech Acquisition Company Unit position as of Q2 2022 after selling out during the quarter.
Wolverine Asset Management sold 1,028 Biotech Acquisition Company Unit shares in Q2 2022, an estimated $10K.
Wolverine Asset Management first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 2 quarters.
Wolverine Asset Management's Biotech Acquisition Company Unit position peaked at $1.93M in Q1 2021.
5 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q2 2022.

Based on Wolverine Asset Management's 13F filing for Q2 2022, filed 3 Aug 2022.